Publication: Timing of clinical interventions in patients with Duchenne muscular dystrophy: A systematic review and grading of evidence
This research article, published in the Journal of Neuromuscular Diseases, provides a review of the impact of timing of clinical interventions in patients with Duchenne muscular dystrophy (DMD)
Learn about the approach taken to evaluate the timing of clinical interventions in patients with DMD
Review the impact of the timing of initiating different clinical interventions on the natural history of the disease
Landfeldt E, Ferizovic N, and Buesch K. J Neuromuscul Dis. 2022; doi: 10.3233/JND-220804. (Epub ahead of print)
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200168 | May 2022
Sign in or register to access exclusive content on this site